Objective:

To evaluate the predictive efficacy of the CHIP Score for major adverse cardiovascular and cerebrovascular events (MACCE) in NSTE-ACS patients and explore risk factors associated with high CHIP scores.

Approach:

Key Findings:

• The CHIP Score effectively stratified NSTE-ACS patients into risk categories for MACCE, which can guide clinical decision-making.
• Higher CHIP Scores correlated with increased rates of adverse events, highlighting the score's predictive value.
• The optimal cut-off value for predicting MACCE was established through ROC analysis, aiding in risk stratification.

Interpretation:

The CHIP Score is a reliable tool for assessing risk in NSTE-ACS patients, aiding in clinical decision-making for interventional treatments.

Limitations:

• Single-center study may limit generalizability, as results may not apply to broader populations.
• Retrospective design may introduce selection bias, affecting the reliability of findings.
• Long-term outcomes beyond 36 months were not evaluated, which may overlook late adverse events.

Conclusion:

The CHIP Score is a promising prognostic tool for identifying high-risk NSTE-ACS patients, warranting further validation in diverse populations to enhance its applicability.

Source

Based on findings from:

Evaluation of a New Prognostic Risk Assessment Tool (CHIP Score) for Interventional Treatment in NSTE-ACS Patients: A Retrospective Cohort Analysis from a Single Center Involving 348 Individuals

Qichang Zhu, Yuan Zhang, Jiaxin Liu, Xin Wang, Jiayu Meng, Hongwei Tian. Bmc Cardiovascular Disorders, 2026.

https://link.springer.com/article/10.1186/s12872-025-05486-x

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.